Ethic Inc. decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 13.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,225 shares of the company's stock after selling 958 shares during the period. Ethic Inc.'s holdings in IDEXX Laboratories were worth $2,574,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors also recently made changes to their positions in the company. Sax Wealth Advisors LLC boosted its position in shares of IDEXX Laboratories by 76.3% during the 4th quarter. Sax Wealth Advisors LLC now owns 1,426 shares of the company's stock valued at $590,000 after purchasing an additional 617 shares in the last quarter. Hantz Financial Services Inc. boosted its position in shares of IDEXX Laboratories by 11.5% during the 4th quarter. Hantz Financial Services Inc. now owns 7,738 shares of the company's stock valued at $3,199,000 after purchasing an additional 800 shares in the last quarter. Paragon Capital Management Inc. boosted its position in shares of IDEXX Laboratories by 25.7% during the 4th quarter. Paragon Capital Management Inc. now owns 3,820 shares of the company's stock valued at $1,579,000 after purchasing an additional 782 shares in the last quarter. Manitou Investment Management Ltd. boosted its position in shares of IDEXX Laboratories by 491.0% during the 4th quarter. Manitou Investment Management Ltd. now owns 52,202 shares of the company's stock valued at $21,582,000 after purchasing an additional 43,369 shares in the last quarter. Finally, Fiera Capital Corp boosted its position in shares of IDEXX Laboratories by 12.3% during the 4th quarter. Fiera Capital Corp now owns 141,198 shares of the company's stock valued at $58,377,000 after purchasing an additional 15,463 shares in the last quarter. Institutional investors own 87.84% of the company's stock.
IDEXX Laboratories Stock Up 1.2%
IDXX stock traded up $6.11 during midday trading on Friday, reaching $518.10. The company had a trading volume of 524,927 shares, compared to its average volume of 649,734. IDEXX Laboratories, Inc. has a 1 year low of $356.14 and a 1 year high of $545.43. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $41.67 billion, a P/E ratio of 48.56, a PEG ratio of 3.41 and a beta of 1.52. The company has a 50 day moving average of $431.28 and a two-hundred day moving average of $431.28.
IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The company had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. During the same quarter in the prior year, the firm earned $2.71 EPS. The company's revenue was up 3.6% compared to the same quarter last year. On average, equities research analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
IDXX has been the subject of several recent analyst reports. Stifel Nicolaus decreased their target price on shares of IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating for the company in a report on Monday, April 14th. Barclays raised their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Piper Sandler raised their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a report on Monday, February 10th. Bank of America raised their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Finally, Morgan Stanley raised their target price on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a report on Monday, May 5th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $524.75.
View Our Latest Research Report on IDEXX Laboratories
About IDEXX Laboratories
(
Free Report)
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
See Also
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
